- Trials with a EudraCT protocol (4)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
4 result(s) found for: NKP46.
Displaying page 1 of 1.
EudraCT Number: 2018-004073-27 | Sponsor Protocol Number: 18082A0002 | Start Date*: 2019-03-13 | |||||||||||
Sponsor Name:ARCI (trade name LYON RECHERCHE CLINIQUE : LyREC) | |||||||||||||
Full Title: Dupilumab impact on skin resident memory T cells | |||||||||||||
Medical condition: Atopic Dermatitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-012083-14 | Sponsor Protocol Number: EPC2008-02 | Start Date*: 2009-06-17 | |||||||||||
Sponsor Name:MEDA Pharma GmbH & Co. KG | |||||||||||||
Full Title: An Open-Label, Multicenter Study of the Effects of Remission Maintenance Therapy with Ceplene® (Histamine Dihydrochloride), Given in Conjunction with Low-Dose Interleukin-2 (IL-2, Proleukin®), on I... | |||||||||||||
Medical condition: Acute Myeloid Leukemia in First Complete Remission (CR1) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) BE (Prematurely Ended) GB (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-001276-38 | Sponsor Protocol Number: ColoAd1-2001 | Start Date*: 2015-10-15 | |||||||||||
Sponsor Name:PsiOxus Therapeutics Ltd | |||||||||||||
Full Title: A Clinical Study Of ColoAd1 Administered Intraperitoneally: Dose Finding and Proof of Concept in Platinum-Resistant Epithelial Ovarian Cancer | |||||||||||||
Medical condition: Epithelial ovarian cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-004601-17 | Sponsor Protocol Number: 1508-GCG | Start Date*: 2017-06-19 | |||||||||||||||||||||
Sponsor Name:European Organisation For Research and Treatment of Cancer (EORTC) | |||||||||||||||||||||||
Full Title: A phase II study of the anti-PDL1 antibody atezolizumab, bevacizumab and acetylsalicylic acid to investigate safety and efficacy of this combination in recurrent platinum-resistant ovarian, fallopi... | |||||||||||||||||||||||
Medical condition: Ovarian neoplasms | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||||||||||||
Trial protocol: ES (Completed) FR (Completed) NL (Completed) GB (GB - no longer in EU/EEA) | |||||||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
